Does PEGCETACOPLAN Cause Choroidal neovascularisation? 52 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Choroidal neovascularisation have been filed in association with PEGCETACOPLAN (Empaveli). This represents 3.8% of all adverse event reports for PEGCETACOPLAN.
52
Reports of Choroidal neovascularisation with PEGCETACOPLAN
3.8%
of all PEGCETACOPLAN reports
1
Deaths
2
Hospitalizations
How Dangerous Is Choroidal neovascularisation From PEGCETACOPLAN?
Of the 52 reports, 1 (1.9%) resulted in death, 2 (3.8%) required hospitalization.
Is Choroidal neovascularisation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEGCETACOPLAN. However, 52 reports have been filed with the FAERS database.
What Other Side Effects Does PEGCETACOPLAN Cause?
Fatigue (135)
Visual impairment (125)
Haemoglobin decreased (106)
Haemolysis (100)
Off label use (97)
Vitreous floaters (78)
Breakthrough haemolysis (67)
Headache (66)
Product dose omission issue (59)
Uveitis (59)
What Other Drugs Cause Choroidal neovascularisation?
RANIBIZUMAB (195)
AFLIBERCEPT (47)
VERTEPORFIN (47)
BEVACIZUMAB (38)
BROLUCIZUMAB-DBLL (38)
PENTOSAN POLYSULFATE (17)
PREDNISONE (10)
SILDENAFIL (10)
LUCENTIS (9)
AVACINCAPTAD PEGOL (7)
Which PEGCETACOPLAN Alternatives Have Lower Choroidal neovascularisation Risk?
PEGCETACOPLAN vs PEGFILGRASTIM
PEGCETACOPLAN vs PEGFILGRASTIM-APGF
PEGCETACOPLAN vs PEGFILGRASTIM-BMEZ
PEGCETACOPLAN vs PEGFILGRASTIM-CBQV
PEGCETACOPLAN vs PEGFILGRASTIM-JMDB